| Title |
Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas
|
|---|---|
| Published in |
Drug Design, Development and Therapy, April 2018
|
| DOI | 10.2147/dddt.s140638 |
| Pubmed ID | |
| Authors |
Jun Gong, Jessica Yan, Charles Forscher, Andrew Hendifar |
| Abstract |
Despite available therapies after initial systemic therapy, prognosis remains poor in relapsed or refractory soft tissue sarcomas (STS). The rational and clinical development of novel agents to improve outcomes in this area of high unmet need is desperately warranted. Aldoxorubicin is a prodrug of doxorubicin that binds to serum albumin immediately after administration through an acid-sensitive hydrazone linker and is subsequently transported to tumor tissues where the acidic environment cleaves the linker and facilitates delivery of a tumor-targeted drug payload. In clinical studies to date, there has been evidence of efficacy and mitigated cardiac toxicity. In this review, we comprehensively detail the clinical development of aldoxorubicin in STS to date. Specifically, we highlight available data on the pharmacokinetics and efficacy from Phase I, Phase II, and Phase III trials in advanced or metastatic STS. We conclude with considerations for future directions of investigation for this promising antitumor agent. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 33% |
| Unknown | 8 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 75% |
| Scientists | 1 | 8% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
| Unknown | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 42 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 19% |
| Student > Ph. D. Student | 7 | 17% |
| Student > Bachelor | 4 | 10% |
| Researcher | 3 | 7% |
| Student > Doctoral Student | 2 | 5% |
| Other | 4 | 10% |
| Unknown | 14 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 9 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 12% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Nursing and Health Professions | 2 | 5% |
| Materials Science | 2 | 5% |
| Other | 6 | 14% |
| Unknown | 16 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 July 2021.
All research outputs
#1,549,426
of 25,382,440 outputs
Outputs from Drug Design, Development and Therapy
#66
of 2,268 outputs
Outputs of similar age
#33,609
of 343,807 outputs
Outputs of similar age from Drug Design, Development and Therapy
#2
of 62 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,807 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.